The nasal spray market has experienced significant growth, driven by the rising prevalence of respiratory conditions and allergies, along with an increasing preference for self-administration therapies. Recent developments include innovations in drug formulations and delivery systems, such as the use of microneedle technology to enhance absorption and minimize discomfort. Furthermore, the emergence of novel biologics and vaccines administered via nasal sprays has gained traction, particularly highlighted during the COVID-19 pandemic. Key players such as Pfizer, Johnson & Johnson, and Novartis are actively investing in research and development to expand their product portfolios. In addition, the rise of over-the-counter (OTC) nasal sprays for allergy relief and congestion management is contributing to market expansion. Regulatory support and favorable reimbursement policies are also enhancing market accessibility, positioning nasal sprays as a vital component of modern therapeutics in respiratory health management.
